Therapeutic Switching of Biological Drugs in Paediatric Severe Asthma: Experience of a Referral Centre. (PubMed, Biomedicines) - Sep 27, 2026 - "Switching occurred from omalizumab to dupilumab (n = 1), mepolizumab to dupilumab (n = 5), and mepolizumab to omalizumab (n = 2)...The daily fluticasone-equivalent dose decreased from a median of 500 μg to 425 μg...These findings highlight the importance of close clinical and functional monitoring to identify children who may benefit from a change in biologic therapy. Larger prospective studies are needed to define standardized criteria and optimal timing for biologic switching in pediatric severe asthma."
Journal • Asthma • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases
|
|
Margherita Amadi; Silvia Carraro; Stefania Zanconato; Valentina Agnese Ferraro; Veronica Ferasin
|